Press

SciSparc’s Collaboration with Clearmind Medicine Continues to Bear Fruit With New Scientific Article Showing MEAI Potential as a Novel Weight Loss Drug

Aug 7 • 3 min read

TEL AVIV, Israel, Aug. 06, 2024 (GLOBE NEWSWIRE) — SciSparc Ltd. (Nasdaq: SPRC) (the “Company” or “SciSparc”), a specialty clinical-stage pharmaceutical company focusing on the development of therapies to treat disorders and rare diseases of the central nervous system, today announced that a new article published by Baraghithy et al. on the promising results from…

Psyched Wellness Announces Supply Chain Disruption in the US

Aug 6 • 2 min read

Toronto, Ontario–(Newsfile Corp. – August 6, 2024) – Psyched Wellness Ltd. (CSE: PSYC) (OTCQB: PSYCF) (FSE: 5U9) (“Psyched”), a life sciences company focused on the production and distribution of health and wellness products, announces that on July 27th, 2024, it was notified of a supply chain disruption at its sole manufacturing facility in the United…

Elaine Elisabetsky, PhD, Member of Jaguar Health’s Mental Health Entheogen Therapeutics Initiative, to Speak August 2nd About Plant-Based Medicines Used to Manage Schizophrenia

Aug 6 • 6 min read

SAN FRANCISCO – Jaguar Health, Inc. (NASDAQ: JAGX) (‘Jaguar’) today announced that Elaine Elisabetsky, PhD, is conducting a talk on Friday, August 2, 2024 from 12:30 PM – 2:00 PM Central covering several decades of research on plant-based medicines used to manage schizophrenia. Dr. Elisabetsky’s talk is part of the annual Norman R. Farnsworth Lecture series at the University of Illinois Chicago (UIC)…

Braxia Scientific Announces Cease Trade Order

Aug 6 • 3 min read

Toronto, Ontario–(Newsfile Corp. – August 5, 2024) – Braxia Scientific Corp. (CSE: BRAX) (OTC Pink: BRAXF) (FWB: 4960), (“Braxia Scientific”, or the “Company”), today announced that the Ontario Securities Commission (the “OSC”) issued a failure-to-file cease trade order (the “FFCTO”) to the Company on August 2, 2024. The FFCTO is a result of the Company’s…

MindBio Therapeutics Appoints Haywood Securities to Conduct Strategic Investment Advisory

Aug 2 • 4 min read

VANCOUVER – MindBio Therapeutics Corp. (CSE: MBIO) (Frankfurt: WF6), (the ‘Company’ or ‘MindBio’), a leading biopharmaceutical company in psychiatric medicine development, is pleased to report that it has appointed Haywood Securities Inc. to act as strategic advisor to the Company to support its near-term objectives. Haywood’s services will focus on assisting the Company to secure potential strategic level investment and…

Pages: 123456789101112131415161718192021222324252627282930313233343536373839404142434445464748495051525354555657585960616263646566676869707172737475767778798081828384858687888990919293949596979899100101102103104105106107108109110111112113114115116117118119120121122123124125126127128129130131132133134135136137138139140141142143144145146147148149150151152153154155156157158159160161162163164165166167168169170171172173174175176177178179180181182183184185186187188189190191192193194195196197198199200201202203204205206207208209210211212213214215216217218219220221222223224225226227228229230231232233234235236237238239240241242243244245246247248249250251252253254255256257258259260261262263264265266267268269270271272273274275276277278279280281282283284285286287288289290291292293294295296297298299300301302303304305306307308309310311312313314315316317318319320321322323324325326327328329330331332333334335336337338339340341342343344345346347348349350351352353354355356357358359360361362363364365366367368369370371372373374375376377378379380381382383384385386387388389390391392393394395396397398399400401402403404405406407408409410411412413414415416417418419420421422423424425426427428429430431432433434435436437438439440441442443444445446447